← Frontiers in Hematology

Papers in Frontiers in Hematology

Page 1 · newest first

1. Case Report: Caplacizumab in a case of very late diagnosis of congenital thrombotic thrombocytopenic purpuraFrontiers in Hematology · 2026
2. Anti-Homer3 antibody-positive autoimmune cerebellar ataxia associated with diffuse large B-cell lymphoma: a case reportFrontiers in Hematology · 2026
3. Case Report: High-level RUNX1/21q22 amplification is associated with multiple cytogenetic abnormalities and TP53 gene mutation in a refractory AML patient with poor clinical outcomeFrontiers in Hematology · 2026
4. Immune surveillance and emerging immunogenetic modifiers in CALR-mutated myeloproliferative neoplasmsFrontiers in Hematology · 2026
5. Non-neoplastic histiocytic proliferations in bone marrow: a case series of uncommon morphologic findingsFrontiers in Hematology · 2026
6. Towards safer and more effective hemotherapy: addressing critical unmet needs in restrictive and liberal blood transfusion strategiesFrontiers in Hematology · 2026
7. Editorial: New molecular targets for personalized treatment for low-grade non-hodgkin lymphomaFrontiers in Hematology · 2026
8. Influence of the pyruvate kinase activator mitapivat (AG-348) on RBC ATP content and export and RBC adhesivity in blood from healthy subjects and sickle cell disease patientsFrontiers in Hematology · 2026
9. Right atrial thrombus in treatment-naive patient with an early-stage classical Hodgkin lymphoma: a case report and review of the literatureFrontiers in Hematology · 2026
10. Associations with the quality of life of adult family members or partners (informal carers) of people with leukaemia: results from a cross-sectional online global surveyFrontiers in Hematology · 2026
11. Matched comparison of therapeutic DLI and second allogeneic transplantation after relapse of acute leukemia or MDSFrontiers in Hematology · 2026
12. The cells of origin of the chemotherapy-curable malignancies are highly sensitive to cytotoxic chemotherapy-mediated cell deathFrontiers in Hematology · 2026
13. A pilot study on therapeutic drug monitoring of asparaginase in Indian children with high-risk ALL: evidence for suboptimal exposureFrontiers in Hematology · 2026
14. Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomasFrontiers in Hematology · 2026
15. Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholdersFrontiers in Hematology · 2026
16. Case Report: Pernicious anemia-associated pancytopenia responds to immunotherapyFrontiers in Hematology · 2026
17. Case Report: A converging pathology: Chediak–Higashi syndrome and IEI-associated lymphoproliferative diseaseSHILAP Revista de lepidopterología · 2026
18. Castleman disease mimicking systemic lupus erythematosus: the importance of vigilance in diagnosing autoimmune mimickersSHILAP Revista de lepidopterología · 2026
19. Single spectral flow cytometry panel for simultaneous detection of hematopoietic stem, progenitor, and mature lineages in mouse bone marrowFrontiers in Hematology · 2026
20. Living with chronic lymphocytic leukaemia: patient perspectives from a global online cross-sectional survey on care pathways and impacts on quality of lifeFrontiers in Hematology · 2026
21. Long-term outcomes of hyperbaric oxygen pretreatment in autologous hematopoietic stem cell transplantationSHILAP Revista de lepidopterología · 2026
22. Evaluating role of TNF-α in tyrosine kinase inhibitors-treated chronic myeloid leukemiaSHILAP Revista de lepidopterología · 2026
23. Case Report: Chronic myelomonocytic leukemia initially diagnosed as immune thrombocytopeniaFrontiers in Hematology · 2026
24. Too soon to switch? Early TKI switching vs. continuous monotherapy: long-term outcomes in chronic myeloid leukemiaFrontiers in Hematology · 2026
25. Case Report: Luspatercept for transfusion-dependent anemia of unknown etiologyFrontiers in Hematology · 2026
26. Myeloma patients’ attitudes and perceived burden of treatment administration routes and locations: insights from a pan-European surveyFrontiers in Hematology · 2026
27. Awareness, acceptability and factors associated with newborn screening for sickle cell disease among pregnant women in a Northern Nigerian Tertiary HospitalFrontiers in Hematology · 2026
28. CRISPR–Cas9 mediated gene therapy in inherited bone marrow failure syndromesFrontiers in Hematology · 2025
29. Knowledge generated in low-and middle-income countries can shape the future of acute leukemia therapies worldwide: the case of Clínica Ruiz in Puebla, MexicoFrontiers in Hematology · 2025
30. A megakaryocyte in the peripheral blood: evidence for pulmonary migration?Frontiers in Hematology · 2025
31. Portuguese real-world experience with ibrutinib for the treatment of relapsed/refractory mantle cell lymphomaFrontiers in Hematology · 2025
32. A focus on LBCL patients in partial remission in the CAR-T eraFrontiers in Hematology · 2025
33. A focus on LBCL patients in partial remission in the CAR-T eraFrontiers in Hematology · 2025
34. Case Report: Extramedullary plasmacytoma of the stomach: a rare manifestation of relapsed multiple myelomaFrontiers in Hematology · 2025
35. The role of interventional radiology in pain management for multiple myeloma: a literature reviewFrontiers in Hematology · 2025
36. Diffuse alveolar hemorrhage in a child with mild hemophilia A who underwent bone marrow transplantation for thalassemia: a case reportFrontiers in Hematology · 2025
37. Immune profile focusing on B-cell activating factor in B-cell malignanciesFrontiers in Hematology · 2025
38. H3K27me3 and HOXA9 expression predict prognosis in pediatric acute myeloid leukemia: an epigenetic-transcriptional correlation studyFrontiers in Hematology · 2025
39. Real-world data of azacitidine for relapsed/refractory nodal T-follicular helper cell lymphoma in 11 patientsFrontiers in Hematology · 2025
40. Real-world experience of venetoclax target dosing with concomitant posaconazole in adult patients with acute myeloid leukemiaFrontiers in Hematology · 2025
41. Case Report: Severe HHV-6-related encephalitis following anti-CD19 CAR-T therapy with no evidence of HHV-6 reactivation in transduced CAR-T cellsFrontiers in Hematology · 2025
42. A perfect storm: the deadly intersection of sickle cell disease and COVID-19Frontiers in Hematology · 2025
43. Case report: A case of intravascular large B-cell lymphoma and related literature reviewFrontiers in Hematology · 2025
44. Balance and management of CRS and infection following CD19-targeted CAR T-cell therapy in primary refractory high-grade B-cell lymphoma: a case reportFrontiers in Hematology · 2025
45. The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?Frontiers in Hematology · 2025
46. Co-occurrence of AIDS and acute promyelocytic leukemia: a case report and review of the literatureFrontiers in Hematology · 2025
47. Soluble immune checkpoint landscape in sickle cell disease links systemic inflammation, autoimmunity, and painFrontiers in Hematology · 2025
48. The “added value” of enrolling hematological patients in clinical trials: a single-center experienceFrontiers in Hematology · 2025
49. Advances in Chimeric Antigen Receptor T-cell therapy for hematologic malignancies and autoimmune conditions: a review of the 2024 American Society of Hematology Annual MeetingFrontiers in Hematology · 2025
50. Case Report: Contrasting outcomes and use of desmosine to monitor two patients treated with plasma cell-directed chemotherapy for gammopathy-driven pulmonary elastolysis in acquired cutis laxaFrontiers in Hematology · 2025